

# **Pilot & Feasibility Grants**

# AN INITIATIVE FUNDED BY NIH/NIDDK P30 DK097512

**DEADLINES** 

Letter of Intent: Monday February 24, 2025 @ 5:00 p.m.

Send to Jeffrey Elmendorf jelmendo@iupui.edu

Application: Monday March 24, 2025

UPLOAD via the Start a Submission link here: Indiana CTSI CDMD Link

Please note that you will be submitting through the Indiana CTSI's grants management software WebCAMP.

The WebCAMP user's guide is available under the funding announcement here:

https://www.indianactsi.org/researchers/funding/open-funding-opportunities/

Contact Jeffrey Elmendorf, Ph.D. jelmendo@ju.edu / 317-274-7852 for RFA questions.

Contact Julie Driscol judrisco@ju.edu / 317-278-2822 for WebCAMP questions.

## INFORMATION FOR APPLICANTS

#### **GENERAL**

A primary research-related activity of the Center for Diabetes and Metabolic Diseases (CDMD)'s Pilot and Feasibility (P&F) Program is to foster the development of new diabetes-related investigators and provide seed-support for innovative, high-risk projects. **For FY25, the program has three different grant mechanisms:** 

- 1. Parent P&F Grants This mechanism will fund up to \$50,000 and invites applications directed towards basic biomedical, clinical, and/or translational research questions on cellular and molecular metabolism related to diabetes/obesity/metabolic syndrome, clinical and outcomes research in diabetes and obesity, complications of diabetes and obesity, islet function and survival, and nutrition and physiology of diabetes and obesity.
- 2. Alzheimer's-Focused P&F Grants This mechanism will fund up to \$50,000 and invites applications focused on diabetes and metabolic disease aspects of Alzheimer's disease and its related dementias (AD/ADRD)—frontotemporal dementia, Lewy body dementia, vascular cognitive impairment with dementia, and multiple etiology dementias.
- 3. Physician-Scientist P&F Grants This mechanism will fund up to \$50,000 and invites applications from exceptional emerging physician-scientists holding an MD (or equivalent) or MD/PhD with a patient-oriented diabetes and/or obesity-related clinical research project, who are early in their clinical research careers and show great promise to develop into future independent investigators.

These funding opportunities invite applications from investigators at Indiana University School of Medicine and other Indiana University campuses (IU Bloomington, IU Muncie, etc.), Purdue University, University of Notre Dame and the Indiana Biomedical Research Institute (IBRI). The campuses are ideal for establishing interdisciplinary collaborations and forging new partnerships between basic scientists and clinical researchers, and such collaborations are encouraged. Work supported by these funds is expected to lead to submissions of major extramural grants (R01/equivalent NIH, major foundation awards, DOD, etc.).

The program is directed at new investigators without current or past NIH research support as a PD/PI with any current or past support from other sources being modest (Category 1) and established investigators with no previous work in diabetes who wish to apply their expertise to a problem in diabetes research (Category 2). The program also considers established investigators in diabetes who propose testing innovative ideas that represent clear departure from ongoing research interests (Category 3) and investigators developing new research techniques/technologies that could be used in an CDMD Core facility (Category 4).

#### **ELIGIBILITY**

All eligible investigators must have faculty appointments, be independent investigators and have the education, skills, knowledge, and resources necessary to carry out the proposed research. National and international collaborations are allowed. Postdoctoral fellows or their equivalent are not eligible.

New investigators, as defined by the NIH, should not have previously competed successfully for a substantial (e.g., R01) NIH-supported independent research award (see <a href="http://grants.nih.gov/grants/new">http://grants.nih.gov/grants/new</a> investigators/#definition).

Note that established non-diabetes and diabetes-related investigators with previous and/or ongoing substantial NIH-supported independent research awards can submit applications pursuing high impact/high risk projects or projects that are a significant departure from their usual work.

#### RESTRICTIONS/ALLOWABLE EXPENSES

- 1. All budgets must have a start date of June 1, 2025.
- 2. Costs may not exceed \$50,000.
- 3. Budget requests may not include indirect costs, F&A, or PI salaries.

- 4. Travel budget requested must be limited to those expenses necessary to carry out the specific aims of the proposed project. Travel to conferences or seminars are not an allowable expense.
- 5. Graduate student stipends (only) are an allowable expense.
- 6. Publication fees are deemed an allowable expense.

#### **APPLICATION & SUBMISSION PROCESS**

The letter of intent is to include: 1) Title of proposal; 2) Name and affiliation of participants in the project; 3) Summary of proposal (*Limit of 300 words*); and 4) An indication of which core facilities of the CDMD will be utilized (See the <u>CDMD Research Cores link</u> for available resources) Submit the letter of intent directly to Jeffrey Elmendo@iu.edu

### **Application**

The 2025 P&F Grant Application Form containing detailed instructions and all the required parts can be downloaded from the Start a Submission link <u>Indiana CTSI CDMD Link</u>. Application narratives should follow the sequence provided in the application form and be single spaced in at least 11-point Arial, Helvetica, Palatino Linotype or Georgia typeface, using 0.5 inch margins.

#### MECHANISM FOR SUBMISSION OF APPLICATION

- 1. Applications will be considered one time per year.
- 2. Submit the letter of intent directly to Jeffrey Elmendorf at <a href="mailto:jelmendo@iu.edu">jelmendo@iu.edu</a>
- 3. Submit the proposal via uploading to the CTSI Grants Management mechanism using the Start a Submission link here: Indiana CTSI CDMD Link

#### **POST AWARD REQUIREMENTS**

- Awards <u>cannot</u> be given without proof of any applicable regulatory documentation. It is, therefore, important that applicants be ready to submit any necessary IACUC/IRB documents at the time of award notification.
- 2. Any publications and/or grant submissions should acknowledge the CDMD P&F program and this award, as well as any CDMD cores used, supported by P30DK097512.
- 3. Completion of an online final progress report due Friday August 21, 2026 at 5:00 p.m.
- 4. Presentation of findings to the CDMD investigators at one or more CDMD sponsored events.
- 5. Online update reports are due on **Friday August 20**, **2027**, and **Friday August 18**, **2028 at 5:00 p.m.**; submitted at one and two years post submission of the final progress report.
- 6. Notification to the P&F Director, in writing, if you leave your institution before the project is complete and/or if the project is transferred to another PI.